| 1 | High Frame Rate Contrast-enhanced Ultrasound Helps Differentiate Malignant and Benign Focal Liver Lesions显示文摘Background and Aims:This study aimed to evaluate the diagnostic performance of high frame rate contrast-en-hanced ultrasound(H-CEUS)of focal liver lesions(FLLs).Methods:From July 2017 to June 2019,conventional con-trast-enhanced ultrasound(C-CEUS)and H-CEUS were per-formed in 78 patients with 78 nodules.The characteristics of C-CEUS and H-CEUS in malignant and benign groups and the differences between different lesion sizes(1-3 cm,3-5 cm,or>5 cm)of C-CEUS and H-CEUS were examined.The diagnostic performance of C-CEUS and H-CEUS was ana-lyzed.The chi-square test or Fisher’s exact test was used to assess inter-group differences.The receiver operating characteristic curve was plotted to determine the diagnostic performance of C-CEUS and H-CEUS.Results:There were significant differences in the enhancement area,fill-in direc-tion and vascular architecture between C-CEUS and H-CEUS for both benign and malignant lesions(all p=0.000-0.008),but there were no significant differences in washout results(p=0.566 and p=0.684,respectively).For lesions 1-3 cm in size,the enhancement area,fill-in direction,and vascular architecture on C-CEUS and H-CEUS were significantly dif-ferent(all p=0.000),unlike for lesions 3-5 cm or>5 cm in size.For differentiation of malignant from benign FLLs in the 1-3 cm group,H-CEUS showed sensitivity,specific-ity,accuracy,and positive and negative predictive values of 92.86%,95.0%,96.3%,90.48%and 93.75%,respectively,which were higher than those for C-CEUS(75.0%,70.0%,77.78%,66.67%and 72.91%,respectively).Conclusions:H-CEUS provided more vascular information which could help differentiate malignant from benign FLLs,especially for lesions 1-3 cm in size. | Xiang Fei Peng Han Bo Jiang Lianhua Zhu Wenshuo Tian Maodong Sang Xirui Zhang Yaqiong Zhu Yukun Luo | 2022 | Journal of Clinical and Translational Hepatology2022，10，1： | 8 |
| 3 | The hippo kinases MST1/2 in cardiovascular and metabolic diseases:A promising therapeutic target option for pharmacotherapy显示文摘Cardiovascular diseases(CVDs)and metabolic disorders are major components of noncommunicable diseases,causing an enormous health and economic burden worldwide.There are common risk factors and developmental mechanisms among them,indicating the far-reaching significance in exploring the corresponding therapeutic targets.MST1/2 kinases are well-established proapoptotic effectors that also bidirectionally regulate autophagic activity.Recent studies have demonstrated that MST1/2 influence the outcome of cardiovascular and metabolic diseases by regulating immune inflammation.In addition,drug development against them is in full swing.In this review,we mainly describe the roles and mechanisms of MST1/2 in apoptosis and autophagy in cardiovascular and metabolic events as well as emphasis on the existing evidence for their involvement in immune inflammation.Moreover,we summarize the latest progress of pharmacotherapy targeting MST1/2 and propose a new mode of drug combination therapy,which may be beneficial to seek more effective strategies to prevent and treat CVDs and metabolic disorders. | Yunfei Yin Mingyue Tan Lianhua Han Lei Zhang Yue Zhang Jun Zhang Wanqian Pan Jiaxiang Bai Tingbo Jiang Hongxia Li | 2023 | Acta Pharmaceutica Sinica B2023，13，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员